Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted by ticks. Our firm offers integrated Lyme disease vaccine and therapy development services which we present with pride as a foremost research services provider.
Introduction to Lyme Disease
Tick bites are the predominant cause of Lyme disease. This system illness, in essence, is a complicated infection. The transmission of this complicated disease is done with the aid of black-legged ticks in parts of North America and the sheep tick in Europe. The skin, joints, the heart and the nervous system are all organs which can be severely infected. When the drying rash erythema migrans accompanies flu like symptoms as a fever, fatigue, headaches, and marks soreness in the joints and muscles then it is a sign of early development of this disease which tends to affect a person's body for quite the long time.
Fig. 1 The enzootic cycle of Borrelia burgdorferi. (Radolf J. D., et al., 2021)
Pathogenesis of Lyme Disease
Lyme disease is caused at the time when the Borrelia burgdorferi bacterium is injected into the human body during a tick bite. After entering the human body, such spirochete bacteria would spread to and infect remoter tissues. Surface proteins presented by the bacteria are changed so that they would escape from the immune response of the host and persist there as a chronic infection.
The immune response in case of Borrelia burgdorferi encompasses innate immune mechanisms but also sustained inflammation resulting in tissue damage B cell activation approaches. Innate immune cells recognize the bacteria and respond by developing inflammation. The bacteria, however, also evolved mechanisms to evade and suppress the immune system which further aids the development of such persistent infection. Important for the control of the infection are antibodies formed in the course of the adaptive immune response.
Vaccine Development for Lyme Disease
In the domain of infectious disease research, considerable emphasis has been put on the development of an efficient Lyme disease vaccine. A while ago, a recombinant vaccine known as LYMErix, was produced which was aimed at a surface protein of Borrelia burgdorferi. However, it is not commercially available currently owing to a low economic viability, concerns about side effects, among other issues.
Ongoing research and development efforts seek to improve currently available forms as well as develop new vaccines to combat Lyme disease in spite of these roadblocks. The primary goal of these vaccines is to remove Borrelia burgdorferi specific surface proteins so as to induce a protective immune response. Innovative adjuvants, subunit vaccines, and DNA vaccines among other techniques are being tested out to improve the effectiveness of the vaccine.
Therapeutics Development for Lyme Disease
Doxycycline, amoxicillin, cefuroxime axetil, and azithromycin are the important antibiotics which form a major part of the Lyme disease treatment regimen. In case of early localized forms of infection, a dentist is likely to prescribe an oral dose of doxycycline. At times, alternative forms of antibiotics like amoxicillin, cefuroxime axetil and azithromycin may be prescribed. In the case of more severe forms, for example, where neurologic or cardiovascular complications are present, intravenous injection of either ceftriaxone or cefotaxime is indicated.
Our team of researchers and scientists have hands on experience and, therefore, strive to assist you in every way during the therapeutic development phase. For more information, click on the link below.
Our Services
Here at our firm, we aim to enhance the research and drug development for Lyme disease. We are motivated to get there with our skills in vaccine devising, developing therapies plus creating trustworthy animal and in vitro models. In fostering the development of potential therapies for Lyme disease, we provide a complete suite of services which is meant to satisfy the needs of multinational pharmaceutical companies.
Infectious Disease Models
- Mouse Infection
- Rhesus Monkey Infection
- Hamster Infection
- Guinea Pig Infection Models
- Rabbit Infection
- Dog Infection
- Cell-based
- Organoid
We have a world-class team that aims to identify new therapeutic targets, develop innovative drug candidates and vaccines, and conduct comprehensive preclinical studies. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and obtain a detailed quotation for the services you require.
References
- Radolf Justin D., et al. "Lyme disease in humans." Current issues in molecular biology 42.1 (2021): 333-384.
- Chen Wen-Hsiang, et al. "Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights." Expert review of vaccines 21.10 (2022): 1405-1417.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
